Core Laboratories Nv Stock Performance
| CLB Stock | USD 17.75 0.79 4.26% |
The firm shows a Beta (market volatility) of 0.5, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Core Laboratories' returns are expected to increase less than the market. However, during the bear market, the loss of holding Core Laboratories is expected to be smaller as well. At this point, Core Laboratories has a negative expected return of -0.11%. Please make sure to confirm Core Laboratories' kurtosis, day median price, and the relationship between the potential upside and daily balance of power , to decide if Core Laboratories performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Core Laboratories NV has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest conflicting performance, the Stock's essential indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return (4.26) | Five Day Return (9.94) | Year To Date Return (2.79) | Ten Year Return (81.86) | All Time Return 491.67 |
Forward Dividend Yield 0.0022 | Payout Ratio | Last Split Factor 2:1 | Forward Dividend Rate 0.04 | Dividend Date 2024-11-25 |
1 | Is the Options Market Predicting a Spike in CORE LABS INC Stock | 11/07/2024 |
2 | Is Core Laboratories Using Too Much Debt | 11/12/2024 |
| Core Laboratories dividend paid on 25th of November 2024 | 11/25/2024 |
3 | Disposition of 227 shares by Sow Teo of Core Laboratories at 20.42 subject to Rule 16b-3 | 11/29/2024 |
4 | Zacks Research Has Pessimistic Outlook of CLB Q4 Earnings - MarketBeat | 12/06/2024 |
5 | Is Now the Right Time to Buy Core Laboratories After Its 12 percent YTD Rise | 12/13/2024 |
6 | Disposition of 9604 shares by Mark Tattoli of Core Laboratories subject to Rule 16b-3 | 12/31/2024 |
7 | CORE LABORATORIES ANNOUNCES TIMING OF FOURTH QUARTER 2024 EARNINGS RELEASE AND CONFERENCE CALL | 01/03/2025 |
8 | Heres Why Hold Strategy is Apt for Core Laboratories Stock Now | 01/15/2025 |
9 | Core Labs Delivers Mixed Q4 Heres Why The Free Cash Flow Explosion Matters - StockTitan | 01/29/2025 |
| Begin Period Cash Flow | 15.4 M |
Core |
Core Laboratories Relative Risk vs. Return Landscape
If you would invest 1,931 in Core Laboratories NV on November 2, 2024 and sell it today you would lose (156.00) from holding Core Laboratories NV or give up 8.08% of portfolio value over 90 days. Core Laboratories NV is generating negative expected returns assuming volatility of 2.7409% on return distribution over 90 days investment horizon. In other words, 24% of stocks are less volatile than Core, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Core Laboratories Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Core Laboratories' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Core Laboratories NV, and traders can use it to determine the average amount a Core Laboratories' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0388
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLB |
Estimated Market Risk
| 2.74 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Core Laboratories is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Core Laboratories by adding Core Laboratories to a well-diversified portfolio.
Core Laboratories Fundamentals Growth
Core Stock prices reflect investors' perceptions of the future prospects and financial health of Core Laboratories, and Core Laboratories fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Core Stock performance.
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0589 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 1.04 B | ||||
| Shares Outstanding | 46.95 M | ||||
| Price To Earning | 101.74 X | ||||
| Price To Book | 3.47 X | ||||
| Price To Sales | 1.59 X | ||||
| Revenue | 509.79 M | ||||
| Gross Profit | 106.98 M | ||||
| EBITDA | 70.42 M | ||||
| Net Income | 37.02 M | ||||
| Cash And Equivalents | 15.43 M | ||||
| Cash Per Share | 0.29 X | ||||
| Total Debt | 215.38 M | ||||
| Debt To Equity | 1.29 % | ||||
| Current Ratio | 2.23 X | ||||
| Book Value Per Share | 5.34 X | ||||
| Cash Flow From Operations | 24.79 M | ||||
| Earnings Per Share | 0.54 X | ||||
| Market Capitalization | 833.36 M | ||||
| Total Asset | 586.39 M | ||||
| Retained Earnings | 120.76 M | ||||
| Working Capital | 135.04 M | ||||
| Current Asset | 238.55 M | ||||
| Current Liabilities | 120.76 M | ||||
About Core Laboratories Performance
By analyzing Core Laboratories' fundamental ratios, stakeholders can gain valuable insights into Core Laboratories' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Core Laboratories has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Core Laboratories has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 56.66 | 59.49 | |
| Return On Tangible Assets | 0.07 | 0.07 | |
| Return On Capital Employed | 0.10 | 0.09 | |
| Return On Assets | 0.06 | 0.10 | |
| Return On Equity | 0.19 | 0.32 |
Things to note about Core Laboratories performance evaluation
Checking the ongoing alerts about Core Laboratories for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Core Laboratories help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Core Laboratories generated a negative expected return over the last 90 days | |
| Core Laboratories is unlikely to experience financial distress in the next 2 years | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Core Labs Delivers Mixed Q4 Heres Why The Free Cash Flow Explosion Matters - StockTitan |
- Analyzing Core Laboratories' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Core Laboratories' stock is overvalued or undervalued compared to its peers.
- Examining Core Laboratories' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Core Laboratories' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Core Laboratories' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Core Laboratories' stock. These opinions can provide insight into Core Laboratories' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Core Stock analysis
When running Core Laboratories' price analysis, check to measure Core Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Core Laboratories is operating at the current time. Most of Core Laboratories' value examination focuses on studying past and present price action to predict the probability of Core Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Core Laboratories' price. Additionally, you may evaluate how the addition of Core Laboratories to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |